GlaxoSmithKline appears to be the frontrunner to buy Pfizer's consumer healthcare business after Reckitt Benckiser said that it ended its interest in the unit.
Reckitt Benckiser’s feelings about Pfizer’s consumer unit haven’t changed since the company said in 2015 that it’d be keen to buy it. But its resources have.